ALGENEX and BIOKIT sign a license agreement for recombinant antigens production to develop diagnostics kits
ALGENEX and BIOKIT sign a non-exclusive license agreement for IBES® technology to make faster high quality recombinant proteins for Diagnostics.
ALGENEX and BIOKIT are proud to announce the closing of a worldwide, non- exclusive license agreement for BIOKIT to use IBES® technology in its next generation in vitro diagnostics for human use. Under the license agreement, BIOKIT will produce a broad range of recombinant proteins. For many years BIOKIT has been operating advanced biotechnology capabilities and has been manufacturing native and recombinant proteins for internal use as well as for supply to the main diagnostics companies worldwide.
“We believe that with this IBES® technology license we confirm our leadership position in bringing to market innovative and high quality diagnostic kits faster, benefitting the clinical labs and professionals we serve and ultimately contributing to the well-being of patients. ALGENEX technology allows us to design better, develop faster and manufacture under very competitive conditions our constantly expanding range of diagnostic kits. The first two products already developed with ALGENEX over the last 3 years are BIO-FLASH HSV-1 IgG (launched now at MEDICA in Q4 2013) and BIO-FLASH HSV-2 IgG (scheduled for Q2 2014). We have already a third IBES®-based protein in an advanced stage of R&D and several other proteins in the pipeline” says Dr Pau Bruguera, head of R&D for Biokit.
“It goes without saying that a global license to a partner like BIOKIT is for ALGENEX a major validation of its capacity to develop and deliver difficult to produce proteins to a demanding market from a quality, from a production flexibility and from a cost- of-goods point of view. Baculovirus based technologies (BEVS) are these days amongst the most preferred ways of producing biologics. For a decade, we have noticed an increased demand coming from not just small biotechs but, increasingly, also from the larger pharmaceutical companies. With this deal with BIOKIT, we also confirm our business model; we strongly believe that novel technologies should be as close as possible to the end user, which is the reason why we are improving continuously and adapting our innovative technologies, IBES® and TopBac®, so as to meet the customers’ needs. The BIOKIT license agreement is for us the shortest way to the end market and a faster way to success!”says Dr. Jose Escribano, founder and scientific advisor for ALGENEX.
Biokit is a Spanish company which develops and manufactures in vitro diagnostics kits for the detection of infectious diseases, coagulation disorders, and others. Using various immunoassay formats, from manual, rapid agglutination tests, to fully-automated, high-sensitivity magnetic-particle-based chemiluminescent systems, Biokit has developed a broad portfolio of products that are distributed, either under its own brand name or under the brand name of the most important diagnostics companies worldwide. The use of recombinant or native proteins, antigens and antibodies, developed and/or purified using last-generation technologies by the internal Biotechnology department guarantees the optimal control of the raw materials which is the basis for the outstanding performance of the assays. The company was created in 1973 and it is part of Werfen, the international group headquartered in Barcelona.
Algenex is a Spanish biotech company involved in developing new platforms which are more versatile and more powerful, to produce high added value protein molecules for both human and animal health in a cost-effective manner. Algenex has developed two disruptive platforms within a baculovirus expression vector system (BEVS) to achieve these goals. Top-Bac® is a proprietary expression cassette that improves the quality of protein produced and in most cases quadruplicates the production over conventional BEVS in insect cells. The other platform of Algenex is IBES®, which is based on the use of insect larvae as disposable, living bioreactors. The combination of both platforms leads to unprecedented production yields for BEVS-based technologies.